Market Research Report - 248658
Human Insulin Market in China 2011-2015
|Published by||TechNavio (Infiniti Research Ltd.)|
|Published||Content info||39 Pages|
This publication has been discontinued on November 12, 2015.
TechNavio's analysts forecast the Human Insulin market in China to grow at a CAGR of 19.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increase in the diabetic population in China. The Human Insulin market in China has also been witnessing increased number of corporate agreements. However, the high cost of human insulin could pose a challenge to the growth of this market.
TechNavio's report, the Human Insulin Market in China 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on China; it also covers the Human Insulin market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Eli Lilly and Co., Novo Nordisk A/S, Sanofi SA, and Tonghua Dongbao Pharmaceutical Co. Ltd. The report also includes other vendors such as Abbott Laboratories Inc., Bayer Healthcare AG, Wockhardt Ltd., Piramal Healthcare Ltd., Glenmark Pharmaceuticals Ltd., SciGen Ltd., Gan & Lee Pharmaceutical Ltd., Wangbang Pharma Group Corp., Pfizer Inc., and Zhuhai United Laboratories Inc.